Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | CETP | P11597 | 2/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25622767 | 1.00 | TACR1 (0.34) | TACR1ALDH1A1EEF2KNOTUMMAPT | |
| SCHEMBL24036736 | 1.00 | TACR1 (0.34) | TACR1ALDH1A1EEF2KNOTUMMAPT | |
| SCHEMBL24036739 | 0.93 | CXCR2 (0.36) | ALDH1A1EEF2KMAPTCETPCTSA | |
| SCHEMBL24036735 | 0.93 | CETP (0.32) | TACR1ALDH1A1EEF2KNOTUMCETP | |
| SCHEMBL25753551 | 0.93 | CETP (0.32) | TACR1ALDH1A1EEF2KNOTUMCETP | |
| SCHEMBL24036737 | 0.93 | CXCR2 (0.36) | TACR1ALDH1A1EEF2KNOTUMMAPT | |
| SCHEMBL25753562 | 0.93 | CXCR2 (0.36) | ALDH1A1EEF2KMAPTCETPCTSA | |
| SCHEMBL25753553 | 0.93 | CXCR2 (0.36) | TACR1ALDH1A1EEF2KNOTUMMAPT | |
| SCHEMBL30388831 | 0.92 | SLC13A3 (0.35) | EEF2KMAPTCETPCTSAGPR35 | |
| SCHEMBL25753540 | 0.92 | SLC13A3 (0.35) | EEF2KMAPTCETPCTSAGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | TACR1 1449/4885ALDH1A1 208/4885EEF2K 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.